 new chemotherapi ovarian cancer system intraperiton podophyllotoxin epipodophyllotoxin deriv possibl use treatment ovarian cancer studi variabl dose prior treatment major influenc outcom respons rate seri teniposid overal respons rate complet respons rate studi etoposid studi activ oral etoposid patient variou prior chemotherapi firm conclus activ etoposid result expect synergi etoposid cisplatin sever studi platin compound system intraperiton IP variou studi intraven drug combin agent untreat patient studi carboplatin cisplatin failur untreat patient promin toxic studi respons cisplatin studi analog combin IP favor experi univers california san diego group investig incorpor etoposid first-lin strategi pharmacolog advantag etoposid IP rout high protein appropri dose intens IP diseas system toxic system dose intens autolog bone marrow support promis etoposid combin high-dos drug